P4, N=1511, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

She was initially managed conservatively with stress-dose hydrocortisone and low-dose cabergoline under close clinical and visual monitoring...Postoperatively, she developed cerebrospinal fluid rhinorrhea that resolved with lumbar drainage, as well as transient diabetes insipidus treated with desmopressin...In hemorrhagic sellar lesions, markedly elevated prolactin may reflect either a prolactinoma or stalk effect; a rapid postoperative prolactin decline supports stalk compression as the dominant mechanism. Close observation during conservative management is essential, and clinical deterioration should prompt timely surgical decompression to optimize neurological and endocrine outcomes.

P=N/A, N=90, Not yet recruiting, Huazhong University of Science and Technology

P1, N=31, Active, not recruiting, Albert Einstein College of Medicine | Phase classification: P2 --> P1

A patient with biopsy-proven VRL underwent longitudinal vitreous cytokine analysis during intravitreal methotrexate (MTX) and dexamethasone (DEX) therapy. Co-expression of IL-10 and IL-May 16, reflect a dynamic interaction between lymphoma cells and the TME, contributing to immune modulation and treatment resistance. Longitudinal IL-16 monitoring may provide additional insight into disease activity and therapeutic response; however, this requires validation in larger VRL cohorts, ideally including inflammatory controls.

P=N/A, N=116, Recruiting, Universidad de La Frontera

P4, N=61, Completed, University of Alberta | Active, not recruiting --> Completed | N=90 --> 61 | Trial primary completion date: Dec 2025 --> Sep 2025

Strikingly, VHL-deficient ccRCC exhibits greater on-target pathway sensitivity to dexamethasone at the H4K12la-glycolysis axis, and glucocorticoid dexamethasone potentiated the antitumor efficacy of the HIF-2α inhibitor belzutifan in both orthotopic cell line-derived and patient-derived xenograft models. Collectively, our findings establish H4K12la as a metabolic‒epigenetic amplifier in VHL-deficient ccRCC, reposition glucocorticoids as epigenetically active modulators that dampen lactate-driven chromatin activation and glycolytic output, and provide a mechanistically grounded combination strategy with HIF-2α blockade to target lactate-fueled transcriptional dependence in metabolically rigid tumors.

P4, N=105, Completed, Fayoum University

The enhanced protective effects of the STF-COS combination are likely attributable to their complementary pharmacological properties, with sulfated fucoidan mediating anti-inflammatory activity and low-molecular-weight COS enhancing bioavailability and epithelial repair. These findings provide experimental evidence supporting the ethnopharmacological potential of combined marine-derived polysaccharides as natural therapeutic candidates for intestinal inflammatory disorders.

P4, N=90, Completed, Poznan University of Medical Sciences | Recruiting --> Completed | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Jul 2025 --> Mar 2026

P=N/A, N=105, Not yet recruiting, Tanta University